MLN8054

Catalog No: tcsc0010

Available Sizes

Size: 5mg

Size: 10mg

Size: 50mg

Size: 100mg

Specifications

CAS No:

869363-13-3

Formula:

$C_{25}H_{15}ClF_2N_4O_2$

Pathway:

Cell Cycle/DNA Damage;Epigenetics

Target:

Aurora Kinase;Aurora Kinase

Purity / Grade:

>98%

Solubility:

DMSO : 30 mg/mL (62.91 mM; Need ultrasonic and warming)

Observed Molecular Weight:

476.86

Product Description

MLN8054 is a potent, selective and orally available **aurora A** kinase inhibitor with an **IC$_{50}$** of 4 nM.

Web: www.taiclone.com
Tel: +886-2-2735-9682
Email: order@taiclone.com

IC50 & Target: IC50: 4 nM (Aurora A), 172 nM (Aurora B)[1]

In Vitro: MLN8054 is an ATP-competitive, reversible inhibitor of recombinant Aurora A kinase. MLN8054 is >40-fold more selective for Aurora A compared with the family member Aurora B. MLN8054 selectively inhibits Aurora A over Aurora B in cultured human tumor cells. MLN8054 treatment results in G2/M accumulation and spindle defects and inhibits proliferation in multiple cultured human tumor cells lines. MLN8054 effectively inhibits the growth of cells from diverse tissue origins with IC_{50} values ranging from 0.11 to 1.43 μM[1]. Treatment of human tumor cells grown in culture with MLN8054 shows a number of morphologic and biochemical changes associated with senescence[2].

In Vivo: In the HCT-116 tumor-bearing mice, MLN8054 treatment inhibits tumor growth dose dependently. MLN8054 is generally well tolerated. MLN8054 also inhibits the growth of the PC-3 tumor xenograft in nude mice. MLN8054 Treatment Results in Inhibition of Aurora A, Accumulation of Mitotic Cells, and Apoptosis *in vivo*[1]. MLN8054 selectively inhibits Aurora A kinase activity when dosed at 30 mg/kg. At this dose in HCT116 tumor tissue, MLN8054 has been shown to inhibit Aurora A autophosphorylation, and induce an increase in the Aurora B substrate, pHisH3[2].

All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!